Protective effect of labedipinedilol-A, a novel dihydropyridine-type calcium channel blocker, on myocardial apoptosis in ischemia-reperfusion injury

Life Sciences
Jhy-Chong LiangJwu-Lai Yeh

Abstract

The effects of labedipinedilol-A, a novel dihydropyridine-type calcium channel blocker with alpha-/beta-adrenoceptor blocking activities, on myocardial infarct size, apoptosis and necrosis in the rat after myocardial ischemia/reperfusion (45 min/120 min) were investigated. Ten minutes prior to left coronary artery occlusion, rats were treated with vehicle or labedipinedilol-A (0.25 or 0.5 mg/kg, i.v.). In the vehicle group, myocardial ischemia-reperfusion induced creatine kinase (CK) release and caused cardiomyocyte apoptosis, as evidenced by DNA ladder formation and terminal dUTP deoxynucleotidyltransferase nick end-labeling (TUNEL) staining. Treatment with labedipinedilol-A (0.25 or 0.5 mg/kg) reduced infarct size significantly compared to vehicle group (18.75+/-0.65% and 8.27+/-0.29% vs. 41.72+/-0.73%, P<0.01). Labedipinedilol-A also reduced the CK, CK-MB, lactate dehydrogenase (LDH) and troponin T levels in blood. In addition, labedipinedilol-A (0.5 mg/kg) significantly decreased TUNEL positive cells from 19.21+/-0.52% to 9.73+/-0.81% (P<0.01), which is consistent with absence of DNA ladders in the labedipinedilol-A group. Moreover, labedipinedilol-A pretreatment also decreased calcium content in ischemic-reperfused myocard...Continue Reading

References

Feb 1, 1983·Circulation Research·K Saida, C van Breemen
Dec 1, 1994·Journal of Molecular and Cellular Cardiology·M F AllardD R English
Jan 1, 1996·Life Sciences·L MurphyC P Bianchi
Jan 3, 1997·Clinica Chimica Acta; International Journal of Clinical Chemistry·J Mair
Jun 20, 1998·Circulation Research·A Haunstetter, S Izumo
Jul 23, 1999·Annals of the New York Academy of Sciences·D K DasN Maulik
Jul 23, 1999·Annals of the New York Academy of Sciences·R A Gottlieb, R L Engler
Mar 23, 2000·Cardiovascular Research·Z Q ZhaoJ Vinten-Johansen
Apr 13, 2000·The European Journal of Neuroscience·M V FrantsevaP L Carlen
Jun 30, 2001·European Journal of Pharmacology·Y M LeeM H Yen
Feb 1, 2002·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·I Tong MakWilliam B Weglicki
May 25, 2002·British Journal of Pharmacology·Takeshi IwaiSatoshi Takeo
Jun 14, 2002·Cardiovascular Research·Qing-Dong WangLars Rydén
Jun 27, 2002·Japanese Journal of Pharmacology·Kazuhiko SaekiTakeshi Matsumoto
Aug 3, 2002·Journal of Pineal Research·Yen-Mei LeeMao-Hsiung Yen
Sep 10, 2002·The Journal of Emergency Medicine·John Sarko, Charles V Pollack
Mar 21, 2003·Biochemical and Biophysical Research Communications·Luciano CominaciniV Lo Cascio
May 31, 2003·Journal of Cardiovascular Pharmacology·Miyuki KobaraMasao Nakagawa
Dec 4, 2003·The Journal of Laboratory and Clinical Medicine·Dinender Kumar, Bodh I Jugdutt
Feb 14, 2004·Cardiovascular Research·Frank EeftingPieter A Doevendans
Jun 3, 2004·British Journal of Pharmacology·Hui-Rong LiuXin L Ma

❮ Previous
Next ❯

Citations

Jul 26, 2011·Evidence-based Complementary and Alternative Medicine : ECAM·Shu-Fen LiouJwu-Lai Yeh
Oct 9, 2020·Animals : an Open Access Journal From MDPI·Meng-Fei YuGuo-Hua Hua

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.